<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00681941</url>
  </required_header>
  <id_info>
    <org_study_id>SVCARB00105</org_study_id>
    <secondary_id>ACTRN012606000380594</secondary_id>
    <nct_id>NCT00681941</nct_id>
  </id_info>
  <brief_title>An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not On Dialysis</brief_title>
  <official_title>An Open Label, Dose Titration of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphatemic Chronic Kidney Disease Patients Not On Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Approximately 45 hyperphosphatemic CKD patients not on dialysis will be entered into this
      study at approximately 20 sites within Europe and 5-10 in Australia. The purpose of this
      study is to determine if sevelamer carbonate tablets dosed three times a day (TID) is an
      effective treatment for the control of serum phosphorous levels in hyperphosphatemic CKD
      patients not on dialysis. Total length of participation is approximately 14 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the efficacy of sevelamer carbonate tablets dosed three times per day (TID) with meals on control of serum phosphorus levels</measure>
    <time_frame>Up to day 70</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the safety and tolerability of sevelamer carbonate tablets dosed TID with meals.</measure>
    <time_frame>Up to day 70</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum calcium-phosphorus product</measure>
    <time_frame>Up to day 70</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum lipid profile [total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol]</measure>
    <time_frame>Up to day 70</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent responders [serum phosphorus between 2.7 and 4.6 mg/dL (0.87 and 1.49 mmol/L) inclusive] at Day 56/ET</measure>
    <time_frame>Up to day 70</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Hyperphosphatemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sevelamer Carbonate Tablets Dosed Three Times A Day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevelamer carbonate (Renvela®)</intervention_name>
    <description>Sevelamer Carbonate Tablets Dosed Three Times A Day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A minimum of 120 male and female patients with chronic kidney disease not requiring
             dialysis will be screened for participation in the study.

          -  Men or woman 18 years of age or older

          -  If currently taking phosphate binder(s), willing to stop this and enter a 2 week
             washout period

          -  Willing to avoid any intentional changes in diet such as fasting or dieting

          -  Have the following central laboratory measurements: 1. If not on a phosphate binder, a
             serum phosphorus measurement ≥ 5.5 mg/dL (1.76 mmol/L) at Screening (Visit1). 2. If
             taking a phosphate binder(s) at screening, a serum phosphorus measurement ≥ 5.5 mg/dL
             (1.76 mmol/L) after the two-week washout period at Visit 1a (Day 0).

          -  At Screening (Visit 1), have the following central laboratory measurements: 1.
             25-hydroxyvitamin D ≥ 10 ng/mL 2. iPTH ≤ 800 pg/mL

          -  Willing and able to take sevelamer carbonate alone as a phosphate binder for the
             duration of the study

          -  Willing and able to maintain screening doses of lipid medication, 1,25
             dihydroxyvitamin D, and/or cinacalcet for the duration of the study, except for safety
             reasons

          -  Willing and able to avoid antacids and phosphate binders containing aluminum,
             magnesium, calcium or lanthanum for the duration of the study unless prescribed as an
             evening calcium supplement

          -  If female and of childbearing potential (pre-menopausal and not surgically sterile),
             willing to use an effective contraceptive method throughout study, which includes
             barrier methods, hormones, or IUDs

          -  Expecting not to initiate dialysis for the duration of this study

          -  Considered compliant with phosphate binders (if applicable)

          -  Willing and able to provide informed consent

          -  Has not participated in any other investigational drug studies within 30 days prior to
             enrollment,

          -  Level of understanding and willingness to cooperate with all visits and procedures as
             described by the study personnel

        Exclusion Criteria:

          -  Active bowel obstruction, dysphagia, swallowing disorder or severe gastrointestinal
             (GI) motility disorders

          -  Active ethanol or drug abuse, excluding tobacco use

          -  Use of anti-arrhythmic or anti-seizure medications for arrhythmia or seizure
             disorders.

          -  In the opinion of the investigator, patient has poorly controlled diabetes mellitus,
             poorly controlled hypertension, active vasculitis, HIV infection, or any clinically
             significant unstable medical condition

          -  Pregnant or breast-feeding

          -  Evidence of active malignancy except for basal cell carcinoma of the skin

          -  Unable to comply with the requirements of the study

          -  Known hypersensitivity to sevelamer or any constituents of the study drug

          -  Any other condition, which in the opinion of the investigator will prohibit the
             patient's inclusion in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nephrology Department, Princess Alexandra Hospital</name>
      <address>
        <city>Wooloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renal Unit, The Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renal Research Unit, Launceston General Hospital</name>
      <address>
        <city>Launceston</city>
        <state>Tasmania</state>
        <zip>7250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Melbourne Hospital, Department of Nephrology</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melbourne Renal Research Group, Epworth Medical Centre</name>
      <address>
        <city>Richmond</city>
        <state>Victoria</state>
        <zip>3121</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nyremedicinsk Afdeling, Medicinerhuset</name>
      <address>
        <city>Aalborg</city>
        <zip>DK-9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nefrologisk Afdeling, Hilleroed Sygehus</name>
      <address>
        <city>Hilleroed</city>
        <zip>DK 3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicinsk Afdeling</name>
      <address>
        <city>København</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicinsk Afdeling, nefrologisk, Roskilde Sygehus</name>
      <address>
        <city>Roskilde</city>
        <zip>DK-4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Pompidou, European Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen, Medizinsche Klinik II</name>
      <address>
        <city>Aachen</city>
        <zip>D-52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heimdialysezentrum</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Nierenzentrum</name>
      <address>
        <city>Nürnberg</city>
        <zip>D-90431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stadt Klinken Solingen, Klinik für Nephrologie und Allgemeine Innere Medizin</name>
      <address>
        <city>Solingen</city>
        <zip>D 42653</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrologisches Zentrum</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>D 78054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Hospital, Queen Elizabeth Medical Centre</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2PR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southmead Hospital</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Dialysis Centre</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester General Hospital</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE5 4PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renal Department, The Royal London Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renal &amp; Urology SDU Offices</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renal Dialysis Unit, Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Renal Medicine, Hope Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renal Unit, Queen Alexandra Hospital</name>
      <address>
        <city>Portsmouth</city>
        <state>England</state>
        <zip>PO6 3RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2008</study_first_submitted>
  <study_first_submitted_qc>May 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2008</study_first_posted>
  <last_update_submitted>March 19, 2015</last_update_submitted>
  <last_update_submitted_qc>March 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2015</last_update_posted>
  <responsible_party>
    <name_title>Medical Monitor</name_title>
    <organization>Genzyme Corporation</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

